Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Beverly Alston"'
Autor:
Kathleen V. Fitch, Emma M. Kileel, Sara E. Looby, Markella V. Zanni, Laura R. Sanchez, Carl J. Fichtenbaum, Edgar T. Overton, Carlos Malvestutto, Judith A. Aberg, Karin L. Klingman, Beverly Alston-Smith, Judith Lavelle, Anne Rancourt, Sharlaa Badal-Faesen, Sandra Wagner Cardoso, Anchalee Avihingsanon, Sandesh Patil, Craig A. Sponseller, Kathleen Melbourne, Heather J. Ribaudo, Katharine Cooper-Arnold, Patrice Desvigne-Nickens, Udo Hoffmann, Pamela S. Douglas, Steven K. Grinspoon, on behalf of the REPRIEVE Investigators
Publikováno v:
HIV Research & Clinical Practice, Vol 21, Iss 1, Pp 11-23 (2020)
Background: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin medication can prevent cardiovascular disease in people with HIV. REPRIEVE recentl
Externí odkaz:
https://doaj.org/article/c1bbcd7120594120b0af18d8c43b3e8f
Autor:
David A Wohl, Michelle A Kendall, Judith Feinberg, Beverly Alston-Smith, Susan Owens, Suzette Chafey, Michael Marco, Sharon Maxwell, Constance Benson, Philip Keiser, Charles van der Horst, Mark A Jacobson, A5030 Study Team
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e78676 (2013)
Despite the efficacy and tolerability of modern antiretroviral therapy (ART), many patients with advanced AIDS prescribed these regimens do not achieve viral suppression or immune reconstitution as a result of poor adherence, drug resistance, or both
Externí odkaz:
https://doaj.org/article/b4be981112fd4ebf8025da9646061d18
Autor:
Shahin Lockman, Michael Hughes, Fred Sawe, Yu Zheng, James McIntyre, Tsungai Chipato, Aida Asmelash, Mohammed Rassool, Sylvester Kimaiyo, Douglas Shaffer, Mina Hosseinipour, Lerato Mohapi, Francis Ssali, Margret Chibowa, Farida Amod, Elias Halvas, Evelyn Hogg, Beverly Alston-Smith, Laura Smith, Robert Schooley, John Mellors, Judith Currier, OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team
Publikováno v:
PLoS Medicine, Vol 9, Iss 6, p e1001236 (2012)
Nevirapine (NVP) is widely used in antiretroviral treatment (ART) of HIV-1 globally. The primary objective of the AA5208/OCTANE trial was to compare the efficacy of NVP-based versus lopinavir/ritonavir (LPV/r)-based initial ART.In seven African count
Externí odkaz:
https://doaj.org/article/27a08397ba034760b2046cfd6f10c8b1
Autor:
Kristen Marks, Minhee Kang, Triin Umbleja, Anchalee Avihingsanon, Patcharaphan Sugandhavesa, Andrea L Cox, Hugo Perazzo, Jennifer C Price, Christina Vernon, Stephanie Caruso, Lillian Collins, Shawn Chiambah, Francoise Giguel, Michael A Leonard, Jan Kosmyna, Allegra Cermak, Kevin Knowles, Philip Marzinek, Ceora Beijer, Sara Zabih, Kelvin McKoy, Beverly Alston-Smith, Kenneth E Sherman
Publikováno v:
Open Forum Infectious Diseases. 9
Background Three-dose series of conventional alum-adjuvanted Hepatitis B surface antigen (HBsAg)-based vaccines achieve seroprotection rates (SPRs) of 35-70% in PLWH. HepB-CpG, a HBsAg vaccine adjuvanted with a TLR-9 agonist, achieves high SPR in imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f750ad95724f428a9dc8f7bc96fb9be
https://doi.org/10.1093/ofid/ofac492.1872
https://doi.org/10.1093/ofid/ofac492.1872
Autor:
Pamela S. Douglas, Kathleen V. Fitch, Heather J. Ribaudo, Karin L. Klingman, Myron A. Waclawiw, Laura M. Smeaton, Beverly Alston-Smith, Melissa L Murry, Emma M Kileel, Katharine Cooper-Arnold, Markella V. Zanni, Shashi Sangle, Edward M. Gardner, Steven K. Grinspoon, Patrice Desvigne-Nickens, José Valdez Madruga, Beatriz Grinsztejn, Kate Starr
Publikováno v:
J Infect Dis
Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE glob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405cf19d0def79eaa5fec8b694eed1cf
https://doi.org/10.1093/infdis/jiaa213
https://doi.org/10.1093/infdis/jiaa213
Autor:
Donald D. Anthony, Ashwin Balagopal, Carey L. Shive, David L. Wyles, Sofi Damjanovska, Corinne Kowal, Laura M. Smeaton, Beverly Alston-Smith, Mark S. Sulkowski, Daniel E. Cohen, Debika Bhattacharya
Publikováno v:
J Infect Dis
BackgroundHepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved.M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84191b9120f8116e6daaf74607c5bc50
https://doi.org/10.1093/infdis/jiaa254
https://doi.org/10.1093/infdis/jiaa254
Autor:
Judith Lavelle, Katharine Cooper-Arnold, Craig A. Sponseller, Pamela S. Douglas, Sara E. Looby, Anne Rancourt, Heather J. Ribaudo, Udo Hoffmann, Laura Sanchez, Anchalee Avihingsanon, Carlos Malvestutto, Kathleen Melbourne, Karin L. Klingman, Kathleen V. Fitch, Sandesh Patil, Sharlaa Badal-Faesen, Beverly Alston-Smith, Reprieve Investigators, Emma M Kileel, Steven K. Grinspoon, Judith A. Aberg, Sandra W. Cardoso, Carl J. Fichtenbaum, Edgar T. Overton, Patrice Desvigne-Nickens, Markella V. Zanni
Publikováno v:
HIV Res Clin Pract
BACKGROUND: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin medication can prevent cardiovascular disease in people with HIV. REPRIEVE recentl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2927484968d6a8dbf3ab9220ce230b31
https://doi.org/10.1080/25787489.2020.1733794
https://doi.org/10.1080/25787489.2020.1733794
Autor:
Beverly Alston-Smith, Jeffrey Schmidt, David L. Wyles, Charles S. Venuto, Yoninah S Cramer, Mark S. Sulkowski, Gene D. Morse, Susan L. Rosenkranz, Daniel E. Cohen
Publikováno v:
Br J Clin Pharmacol
Aims AIDS Clinical Trials Group study A5334s evaluated the pharmacokinetics of raltegravir before and during combined administration of ombitasvir, paritaprevir/ritonavir, plus dasabuvir (OBV/PTV/r + DSV) and weight-based ribavirin in human immunodef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed238ea7676a4e36e467368973f6d8d
https://doi.org/10.1111/bcp.14148
https://doi.org/10.1111/bcp.14148
Autor:
Carl J. Fichtenbaum, Markella V. Zanni, Craig A. Sponseller, Michael T. Lu, Steven K. Grinspoon, Judith A. Aberg, Pamela S. Douglas, Katharine Cooper-Arnold, Myron A. Waclawiw, Beverly Alston-Smith, Heather J. Ribaudo, Karin L. Klingman, Carlos Malvestutto, Udo Hoffmann, Judith S. Currier, Kathleen V. Fitch, Patrice Desvigne-Nickens, Edgar T. Overton
Publikováno v:
Am Heart J
Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need exists to develop effective strategies to prevent CVD in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f734b23c93a0ea307f2de9843edd1d2
https://doi.org/10.1016/j.ahj.2018.12.016
https://doi.org/10.1016/j.ahj.2018.12.016
Autor:
Pamela S. Douglas, Beverly Alston-Smith, Myron A. Waclawiw, Udo Hoffmann, Markella V. Zanni, Michael T. Lu, John Sukumar Aluru, Patrice Desvigne-Nickens, Devvora Olalere, Steven K. Grinspoon, Heather J. Ribaudo, Karin L. Klingman, Elizabeth C. Adami, Saeyun Lee, Tricia H. Burdo, Reprieve Investigators, Katharine Cooper-Arnold, Kathleen V. Fitch, Nadja Arifovic, Judith A. Aberg, Alexander R. Ivanov, Edgar T. Overton, Kenneth C. Williams, Carl J. Fichtenbaum, Michael T. Osborne
Publikováno v:
Am Heart J
Background People with HIV (PWH) have increased cardiovascular events, inflammation, and high-risk coronary atherosclerosis. Statin therapy has been shown to lower the risk of cardiovascular disease (CVD) in the general population, but whether this r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f283c109ac640ccb7e3ee083d481fd2
https://doi.org/10.1016/j.ahj.2019.02.011
https://doi.org/10.1016/j.ahj.2019.02.011